{"paper_id":"a067c939-3efa-4b9f-81e4-7d138f30e9b5","body_text":"Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.\nUnintended pregnancies with term delivery following ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation of uterine fibroid and adenomyosis\nAffiliations\nArticle Info\n1 Aegis-Roen Obstetrics and Gynecology Clinic, Seoul, Korea\n2 Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Incheon St. Mary’s Hospital, Incheon, Korea\n3 Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea\nAbstract\nPurpose of Investigation: This study aimed to assess the pregnancy outcome of patients with uterine fibroid or adenomyosis treated by ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation. Materials and Methods: Treatment was administrated using a focused ultrasound tumor therapeutic system. In this study, there were 23 unintended pregnancies after USgHIFU ablation. Results: Twelve patients developed no complication during pregnancy and continued until full term delivery. Vaginal and cesarean section deliveries were also uneventful. The following are the pregnancy outcome of the patients: three patients experienced spontaneous abortions, one patient experienced preterm delivery, and five patients remained pregnant at this point. Conclusions: USgHIFU seems to have the effectiveness to precisely treat adenomyosis and uterine fibroid, allowing for normal reproduction. Well-designed prospective trials are needed to ascertain the safety of this treatment with pregnancy due to the lack of large-scaled study.\nKeywords\n- Adenomyosis\n- HIFU\n- Pregnancy\n- Uterine fibroid","source_license":"CC0","license_restricted":false}